Pfizer buys into decentralized cooperative to accelerate R&D in human longevity
The biggest of Big Pharma is turning over a new, edgier leaf, proposing to spend $500,000 to join a new cooperative, known as VitaDAO, for community-governed and decentralized drug development focused on extending human life.
The cooperative aims to better align various forms of early-stage funding in longevity biopharma through a combo of novel and buzzword-heavy frameworks like decentralized autonomous organizations, non-fungible tokens, and financial engineering tools that run on the Ethereum blockchain.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.